FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167968468> ?p ?o ?g. }

• W2167968468 endingPage "2435" @default.
• W2167968468 startingPage "2425" @default.
• W2167968468 abstract "Abstract The human androgen receptor plays a major role in the development and progression of prostate cancer and represents a well-established drug target. All clinically approved androgen receptor antagonists possess similar chemical structures and exhibit the same mode of action on the androgen receptor. Although initially effective, resistance to these androgen receptor antagonists usually develops and the cancer quickly progresses to castration-resistant and metastatic states. Yet even in these late-stage patients, the androgen receptor is critical for the progression of the disease. Thus, there is a continuing need for novel chemical classes of androgen receptor antagonists that could help overcome the problem of resistance. In this study, we implemented and used the synergetic combination of virtual and experimental screening to discover a number of new 10-benzylidene-10H-anthracen-9-ones that not only effectively inhibit androgen receptor transcriptional activity, but also induce almost complete degradation of the androgen receptor. Of these 10-benzylidene-10H-anthracen-9-one analogues, a lead compound (VPC-3033) was identified that showed strong androgen displacement potency, effectively inhibited androgen receptor transcriptional activity, and possesses a profound ability to cause degradation of androgen receptor. Notably, VPC-3033 exhibited significant activity against prostate cancer cells that have already developed resistance to the second-generation antiandrogen enzalutamide (formerly known as MDV3100). VPC-3033 also showed strong antiandrogen receptor activity in the LNCaP in vivo xenograft model. These results provide a foundation for the development of a new class of androgen receptor antagonists that can help address the problem of antiandrogen resistance in prostate cancer. Mol Cancer Ther; 12(11); 2425–35. ©2013 AACR." @default.
• W2167968468 created "2016-06-24" @default.
• W2167968468 creator A5000851749 @default.
• W2167968468 creator A5008699306 @default.
• W2167968468 creator A5012245576 @default.
• W2167968468 creator A5016242868 @default.
• W2167968468 creator A5016346851 @default.
• W2167968468 creator A5020529282 @default.
• W2167968468 creator A5034843478 @default.
• W2167968468 creator A5042495906 @default.
• W2167968468 creator A5048639910 @default.
• W2167968468 creator A5052295498 @default.
• W2167968468 creator A5059324559 @default.
• W2167968468 creator A5063067549 @default.
• W2167968468 creator A5068981703 @default.
• W2167968468 creator A5070580886 @default.
• W2167968468 creator A5090325831 @default.
• W2167968468 date "2013-11-01" @default.
• W2167968468 modified "2023-10-12" @default.
• W2167968468 title "Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer" @default.
• W2167968468 cites W1981652396 @default.
• W2167968468 cites W1985588649 @default.
• W2167968468 cites W1985803021 @default.
• W2167968468 cites W1992481935 @default.
• W2167968468 cites W1992583240 @default.
• W2167968468 cites W1999506870 @default.
• W2167968468 cites W2006138763 @default.
• W2167968468 cites W2017184248 @default.
• W2167968468 cites W2040123299 @default.
• W2167968468 cites W2050714175 @default.
• W2167968468 cites W2052420006 @default.
• W2167968468 cites W2056634550 @default.
• W2167968468 cites W2084637523 @default.
• W2167968468 cites W2090933256 @default.
• W2167968468 cites W2118906905 @default.
• W2167968468 cites W2119504728 @default.
• W2167968468 cites W2122680090 @default.
• W2167968468 cites W2126253217 @default.
• W2167968468 cites W2128332459 @default.
• W2167968468 cites W2130479394 @default.
• W2167968468 cites W2132665968 @default.
• W2167968468 cites W2150775704 @default.
• W2167968468 cites W2151702398 @default.
• W2167968468 cites W2162411576 @default.
• W2167968468 cites W2170957864 @default.
• W2167968468 cites W2176516200 @default.
• W2167968468 cites W2327568953 @default.
• W2167968468 cites W58950010 @default.
• W2167968468 cites W83502394 @default.
• W2167968468 doi "https://doi.org/10.1158/1535-7163.mct-13-0267" @default.
• W2167968468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23939374" @default.
• W2167968468 hasPublicationYear "2013" @default.
• W2167968468 type Work @default.
• W2167968468 sameAs 2167968468 @default.
• W2167968468 citedByCount "20" @default.
• W2167968468 countsByYear W21679684682014 @default.
• W2167968468 countsByYear W21679684682015 @default.
• W2167968468 countsByYear W21679684682016 @default.
• W2167968468 countsByYear W21679684682017 @default.
• W2167968468 countsByYear W21679684682018 @default.
• W2167968468 countsByYear W21679684682019 @default.
• W2167968468 countsByYear W21679684682020 @default.
• W2167968468 countsByYear W21679684682021 @default.
• W2167968468 countsByYear W21679684682022 @default.
• W2167968468 countsByYear W21679684682023 @default.
• W2167968468 crossrefType "journal-article" @default.
• W2167968468 hasAuthorship W2167968468A5000851749 @default.
• W2167968468 hasAuthorship W2167968468A5008699306 @default.
• W2167968468 hasAuthorship W2167968468A5012245576 @default.
• W2167968468 hasAuthorship W2167968468A5016242868 @default.
• W2167968468 hasAuthorship W2167968468A5016346851 @default.
• W2167968468 hasAuthorship W2167968468A5020529282 @default.
• W2167968468 hasAuthorship W2167968468A5034843478 @default.
• W2167968468 hasAuthorship W2167968468A5042495906 @default.
• W2167968468 hasAuthorship W2167968468A5048639910 @default.
• W2167968468 hasAuthorship W2167968468A5052295498 @default.
• W2167968468 hasAuthorship W2167968468A5059324559 @default.
• W2167968468 hasAuthorship W2167968468A5063067549 @default.
• W2167968468 hasAuthorship W2167968468A5068981703 @default.
• W2167968468 hasAuthorship W2167968468A5070580886 @default.
• W2167968468 hasAuthorship W2167968468A5090325831 @default.
• W2167968468 hasBestOaLocation W21679684681 @default.
• W2167968468 hasConcept C121608353 @default.
• W2167968468 hasConcept C126322002 @default.
• W2167968468 hasConcept C134018914 @default.
• W2167968468 hasConcept C2776551883 @default.
• W2167968468 hasConcept C2777911890 @default.
• W2167968468 hasConcept C2779322244 @default.
• W2167968468 hasConcept C2779723316 @default.
• W2167968468 hasConcept C2780192828 @default.
• W2167968468 hasConcept C2910322876 @default.
• W2167968468 hasConcept C502942594 @default.
• W2167968468 hasConcept C61367390 @default.
• W2167968468 hasConcept C71315377 @default.
• W2167968468 hasConcept C71924100 @default.
• W2167968468 hasConcept C98274493 @default.
• W2167968468 hasConceptScore W2167968468C121608353 @default.
• W2167968468 hasConceptScore W2167968468C126322002 @default.

• next